Intellipharmaceutics International Inc. (NASDAQ:IPCI) has been assigned a $8.00 price target by stock analysts at Brean Capital in a report released on Monday. The brokerage currently has a a “buy” rating on the stock. Brean Capital’s target price indicates a potential upside of 179.72% from the company’s current price.

Other equities research analysts have also issued research reports about the company. Maxim Group set a $6.00 price target on Intellipharmaceutics International and gave the company a “buy” rating in a research report on Saturday. Zacks Investment Research upgraded Intellipharmaceutics International from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research report on Tuesday, June 21st.

Intellipharmaceutics International (NASDAQ:IPCI) traded down 5.24% on Monday, hitting $2.71. The company had a trading volume of 266,044 shares. Intellipharmaceutics International has a one year low of $1.41 and a one year high of $3.33. The company’s market capitalization is $77.90 million. The stock’s 50-day moving average price is $2.09 and its 200 day moving average price is $1.87.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Intellipharmaceutics International (NASDAQ:IPCI) last issued its quarterly earnings data on Friday, October 14th. The company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07). Intellipharmaceutics International had a negative return on equity of 832.00% and a negative net margin of 371.11%. On average, analysts expect that Intellipharmaceutics International will post ($0.28) EPS for the current fiscal year.

An institutional investor recently raised its position in Intellipharmaceutics International stock. Atria Investments LLC increased its position in shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) by 12.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,895 shares of the company’s stock after buying an additional 8,168 shares during the period. Atria Investments LLC owned about 0.26% of Intellipharmaceutics International worth $159,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 1.34% of the company’s stock.

Intellipharmaceutics International Company Profile

IntelliPharmaCeutics International Inc is a Canada-based pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

5 Day Chart for NASDAQ:IPCI

Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with's FREE daily email newsletter.